Ten pharmaceutical giants released the first half of the financial report, who is the king of revenue?

[pharmaceutical network industry trends] at present, ten large multinational pharmaceutical companies including Novartis, Pfizer, AstraZeneca, Roche, GSK, BMS, Johnson & Johnson, Sanofi, Alberto and Bayer have issued financial reports for the first half of 2019 According to the financial report, only BMS and AstraZeneca achieved double-digit growth in revenue Roche's revenue: 30.5 billion Swiss francs (about 30.746 billion US dollars) in the first half of the year, Roche's revenue reached 30.5 billion Swiss francs, up 6% year on year Among them, the revenue of diagnosis business is CHF 6358 million, an increase of 2% over the previous period The second is molecular diagnosis business, with a total revenue of 1.029 billion francs in the first half of 2019, up 6% year on year From the perspective of organizational diagnosis, the total revenue was 526 million francs, a year-on-year decline of - 3%; the reason for the decline was that the sales volume decreased by 3% due to the delay of tool shipment Pfizer's revenue: US $26.382 billion In the second quarter of 2019, Pfizer's revenue was US $13.3 billion Overall, the year-on-year growth was 2%, and the revenue growth mainly came from the biomedical sector It is reported that Pfizer's biomedical sector achieved 6% growth In addition, in the first half of 2019, Pfizer's return to shareholders amounted to $12.9 billion, including $4 billion in dividends and $8.9 billion in share repurchases Novartis Revenue: US $22.87 billion in the first half of 2019, Novartis achieved US $22.87 billion in revenue The main source of growth was Novartis' heart failure drug entresto, whose sales rose 81% to $421 million The drug was approved by FDA and EU in July 2015 and November 2015, respectively In addition, the growth of Novartis tumor drugs was 9% J & J's revenue: 20.073 billion US dollars The second quarter net profit of J & J was 5.61 billion US dollars, an increase of 42% compared with 3.95 billion US dollars in the same period of last year; the earnings per share was 2.08 US dollars, compared with 1.45 US dollars in the same period of last year Excluding an intangible asset amortization note and other special items, J & J's adjusted second quarter earnings per share were $2.58 Sanofi's revenue: US $18.955 billion According to the announcement, Sanofi's net profit attributable to ordinary shareholders in mid-2019 was EUR 1.05 billion, down 40.94% year on year Among them, jianzan, a rare disease drug unit under Sanofi, has achieved a relatively significant revenue growth of about 21.8%, which is mainly due to the continuous landing of dupixent market Alberto's revenue: 16.083 billion US dollars It is reported that among the multinational pharmaceutical companies disclosed in the 2019 half year report, Alberto's performance does not increase but decreases The direct cause is the decline of sales of Sumeria music in the global level In the quarter of 2019, sales of Sumeria music fell, down 5.6% year on year GSK's revenue: US $15.47 billion On July 24, GSK released its 2019q2 performance report, with total revenue of £ 7.8 billion in the second quarter, up 7% at real exchange rate (AER) and 5% at fixed exchange rate (CER) Among them, drug revenue is 4.3 billion US dollars, vaccine revenue is 1.6 billion US dollars, and consumer health business revenue is 1.9 billion pounds BMS Revenue: US $12.193 billion in the first half of 2019, BMS achieved US $12.193 billion in revenue, a year-on-year increase of 12% According to the financial report, the sales volume of elotor in the second quarter has reached 392 million US dollars, an increase of 24% Opdivo grew by 12% with sales of $196 million AstraZeneca's revenue: US $11.314 billion in the first half of the year, AstraZeneca's revenue totaled US $11.314 billion, up 9.49% year on year According to the announcement, AstraZeneca's profit attributable to ordinary shareholders in the mid-2019 financial year was $670 million, down 2.9% year-on-year In AstraZeneca's business, biomedicine accounts for a relatively high proportion, with sales revenue of US $4.629 billion, accounting for 42% Bayer's revenue: 9.774 billion US dollars On July 30, Bayer released the 2019 half year report In the first half of the year, Bayer's revenue increased by 31.6% to 24.5 billion euros compared with the same period last year; EBITDA increased by 16% to 5.624 billion euros; net profit decreased by 40% to 1.645 billion euros Bayer's revenue and EBITDA's substantial growth are mainly due to the acquisition of Monsanto.